Harmony Biosciences Holdings, Inc. [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	S-1/A
Revenues	305.4	159.7	6.0	0.0
Revenue growth	91.2%	2564.6%
Cost of goods sold	55.5	27.7	1.6	0.0
Gross profit	249.9	132.0	4.4	0.0
Gross margin	81.8%	82.6%	73.7%
Selling, general and administrative [+]	132.0	95.6	80.7	29.1
Sales and marketing	68.1	55.8	44.3	16.9
General and administrative	63.9	39.7	36.4	12.2
Research and development	30.4	19.4	69.6	12.4
EBITDA [+]	106.4	27.2	-142.7	-41.3
EBITDA growth	290.7%	-119.1%	245.9%
EBITDA margin	34.8%	17.0%	-2380.2%
Depreciation	0.4	0.4	0.4	0.2
EBITA	106.0	26.8	-143.1	-41.4
EBITA margin	34.7%	16.8%	-2386.8%
Amortization of intangibles	18.4	9.8	2.8
EBIT [+]	87.5	17.0	-145.9	-41.4
EBIT growth	415.3%	-111.6%	252.1%
EBIT margin	28.7%	10.6%	-2433.8%
Interest expense, net [+]	24.0	28.2	6.1	-1.5
Interest expense	24.0	28.2	6.1
Interest income				1.5
Other income (expense), net [+]	-26.1	-25.7
Gain (loss) on debt retirement	-26.1	-22.6
Other	0.0	-3.1
Pre-tax income	37.4	-36.9	-152.0	-39.9
Income taxes	2.8	0.0	0.0	0.0
Tax rate	7.6%	0.0%	0.0%	0.0%
Net income	34.6	-63.8	-187.2	-70.1
Net margin	11.3%	-40.0%	-3122.7%

Basic EPS [+]	$0.60	($2.48)	($24.07)	($7.91)
Growth	-124.3%	-89.7%	204.2%
Diluted EPS [+]	$0.58	($2.48)	($24.07)	($7.91)
Growth	-123.6%	-89.7%	204.2%

Shares outstanding (basic) [+]	57.5	25.8	7.8	8.9
Growth	123.2%	231.4%	-12.2%
Shares outstanding (diluted) [+]	59.2	25.8	7.8	8.9
Growth	129.7%	231.4%	-12.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.